| Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party GJ Schuurhuis, M Heuser, S Freeman, MC Béné, F Buccisano, J Cloos, ... Blood, The Journal of the American Society of Hematology 131 (12), 1275-1291, 2018 | 1060 | 2018 |
| Functional genomic landscape of acute myeloid leukaemia JW Tyner, CE Tognon, D Bottomly, B Wilmot, SE Kurtz, SL Savage, ... Nature 562 (7728), 526-531, 2018 | 1053 | 2018 |
| Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease DB Beck, MA Ferrada, KA Sikora, AK Ombrello, JC Collins, W Pei, ... New England Journal of Medicine 383 (27), 2628-2638, 2020 | 692 | 2020 |
| 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party M Heuser, SD Freeman, GJ Ossenkoppele, F Buccisano, CS Hourigan, ... Blood, The Journal of the American Society of Hematology 138 (26), 2753-2767, 2021 | 383 | 2021 |
| Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease CS Hourigan, LW Dillon, G Gui, BR Logan, M Fei, J Ghannam, Y Li, ... Journal of Clinical Oncology 38 (12), 1273, 2020 | 333 | 2020 |
| Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis NJ Short, S Zhou, C Fu, DA Berry, RB Walter, SD Freeman, CS Hourigan, ... JAMA oncology 6 (12), 1890-1899, 2020 | 257 | 2020 |
| Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis SA Buckley, BL Wood, M Othus, CS Hourigan, C Ustun, MA Linden, ... haematologica 102 (5), 865, 2017 | 256 | 2017 |
| The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia P Williams, S Basu, G Garcia‐Manero, CS Hourigan, KA Oetjen, ... Cancer 125 (9), 1470-1481, 2019 | 255 | 2019 |
| Measurable residual disease testing in acute myeloid leukaemia CS Hourigan, RP Gale, NJ Gormley, GJ Ossenkoppele, RB Walter Leukemia 31 (7), 1482-1490, 2017 | 250 | 2017 |
| Minimal residual disease in acute myeloid leukaemia CS Hourigan, JE Karp Nature reviews Clinical oncology 10 (8), 460-471, 2013 | 236 | 2013 |
| The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor ζ chain MA Purbhoo, JM Boulter, DA Price, AL Vuidepot, CS Hourigan, ... Journal of Biological Chemistry 276 (35), 32786-32792, 2001 | 190 | 2001 |
| Effects of systemically administered hydrocortisone on the human immunome MJ Olnes, Y Kotliarov, A Biancotto, F Cheung, J Chen, R Shi, H Zhou, ... Scientific reports 6 (1), 1-15, 2016 | 166 | 2016 |
| Current approaches in the treatment of relapsed and refractory acute myeloid leukemia NR Ramos, CC Mo, JE Karp, CS Hourigan Journal of clinical medicine 4 (4), 665-695, 2015 | 154 | 2015 |
| Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry KA Oetjen, KE Lindblad, M Goswami, G Gui, PK Dagur, C Lai, LW Dillon, ... JCI insight 3 (23), 2018 | 151 | 2018 |
| American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults MA Sekeres, G Guyatt, G Abel, S Alibhai, JK Altman, R Buckstein, H Choe, ... Blood advances 4 (15), 3528-3549, 2020 | 149 | 2020 |
| Integrative analysis of drug response and clinical outcome in acute myeloid leukemia D Bottomly, N Long, AR Schultz, SE Kurtz, CE Tognon, K Johnson, M Abel, ... Cancer cell 40 (8), 850-864. e9, 2022 | 103 | 2022 |
| Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia ME Percival, C Lai, E Estey, CS Hourigan Blood reviews 31 (4), 185-192, 2017 | 102 | 2017 |
| A novel approach to antigen-specific deletion of CTL with minimal cellular activation using α3 domain mutants of MHC class I/peptide complex XN Xu, MA Purbhoo, N Chen, J Mongkolsapaya, JH Cox, UC Meier, ... Immunity 14 (5), 591-602, 2001 | 99 | 2001 |
| NY-ESO-1 vaccination in combination with decitabine induces antigen-specific T-lymphocyte responses in patients with myelodysplastic syndrome EA Griffiths, P Srivastava, J Matsuzaki, Z Brumberger, ES Wang, J Kocent, ... Clinical Cancer Research 24 (5), 1019-1029, 2018 | 91 | 2018 |
| The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulation M Palangat, DG Anastasakis, DL Fei, KE Lindblad, R Bradley, ... Genes & development 33 (9-10), 482-497, 2019 | 78 | 2019 |
Laura W DillonNational Heart, Lung, and Blood InstituteVerified email at nih.gov
